Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT00294489
Other study ID # ORHCV1-HMO-CTIL
Secondary ID
Status Recruiting
Phase Phase 3
First received February 21, 2006
Last updated February 21, 2006
Start date February 2006
Est. completion date December 2006

Study information

Verified date February 2006
Source Hadassah Medical Organization
Contact Gadi Lalazar, MD
Phone 00 972 6778511
Email lalazar@hadassah.org.il
Is FDA regulated No
Health authority United States: Food and Drug AdministrationIsrael: Israeli Health Ministry Pharmaceutical Administration
Study type Observational

Clinical Trial Summary

A relatively large proportion of patients with chronic HCV infection have normal or mildly elevated ALT. Many of these patients are not being treated, and are not being sent for a liver biopsy. The present study will determine the ability of Methcetin BreathID Test(MBIT) to detect those patients who will be candidates for anti-viral treatment, as an alternative measure for liver biopsy in decision-making prior to treatment in clinical hepatology.


Description:

The rational for using MBIT in the management of HCV in patients with persistently normal (and slightly elevated) ALT:

- If MBIT is impaired, this indicates fibrosis >2: a trigger to begin treatment

- This strategy will enable treating patients with relatively severe disease that was not detected by biopsy.

- HMOs recognize the cost-effectiveness of anti-viral therapy in these patients, as a means of prevention of deterioration, cirrhosis and HCC.

- If MBIT indicates low fibrosis => treatment may be deferred, and follow-up is performed to detect any possible degradation that will indicate need for treatment.

- Today the AASLD guidelines allow for treatment of HCV RNA+ patients with normal ALT. In view of the limited effectivity of therapy, its cost and side effects, there are likely to be many individuals in whom therapy can be safely deferred, leading to cost saving.

- MBIT may replace the need of liver biopsy for decision- making in HCV.

- Even in patients with genotype 1 and elevated ALT, or with risk of side effects, treatment may be delayed in low fibrosis (e.g. <2).

GOAL:

• To assess the ability of the MBIT to improve the management of patients for liver disorders

AIM:

• To determine whether the Methacetin BreathID Test (MBIT) can be useful in evaluation of HCV RNA positive patients with normal or minimally elevated ALT and to determine the severity of their liver disease as a guide for decision-making in routine clinical use.

OBJECTIVE:

AUC>0.75 (+/-10% in 95%CI) in detection of fibrosis>2.

INCLUSION CRITERIA:

- Men or women>18

- Patients with HCV RNA+ above 105 copies Patients with normal liver enzymes on two tests 3 months apart, or up to
- Patients with biopsy proven HCV or (9 months prior to test with no anticipated changes in liver disease since biopsy).

EXCLUSION CRITERIA:

- Other liver disorders.

- Active infections.

- Use of drugs that are known to induce/suppress P4501A2

- Pulmonary diseases

- Consumption of >20cc alcohol a day prior to the test.

NUMBER OF PATIENTS:

- 200 HCV

- 50 matched controls

METHODS:

- Patient selection - All the patients that underwent a liver biopsy in the last 9 months in each center are invited to participate in the study, assuming they meet inclusion/exclusion criteria.

- Patients will undergo MBIT and data will be compared with the results of the different fibrotic and inflammatory scores (i.e. METAVIR) on liver biopsy. One pathologist will re-examine all biopsies.

- Oridion BreathID will provide MBIT data on 50 healthy controls.

- Substrate - A test meal consisting of 75mg PO methacetin + a known surface-active ingredient routinely used in the food and drug industry.

- Test length - 1 hour

- Fasting-8 hours fast only.

- The patient will be attached to the BreathID device via a nasal cannula and after baseline breath is measured, the test meal will be ingested and the device will continue measuring the exhaled breath for 1 hour. The BreathID device automatically measures changes in the 13C/12C ratio due to metabolization of the methacetin, using a spectroscopic principal. The results are printed out automatically at the end of the test.

STUDY DESIGN:

• At first visit to physician, patients will perform viral load test, liver enzymes tests and MBIT. A biopsy will have been performed within 9 months of these tests.


Recruitment information / eligibility

Status Recruiting
Enrollment 500
Est. completion date December 2006
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Men or women>18

- Patients with HCV RNA+ above 105 copies Patients with normal liver enzymes on two tests 3 months apart, or up to <X1.5 of upper normal

- Patients with biopsy proven HCV or (9 months prior to test with no anticipated changes in liver disease since biopsy).

Exclusion Criteria:

- Other liver disorders.

- Active infections.

- Use of drugs that are known to induce/suppress P4501A2

- Pulmonary diseases

- Consumption of >20cc alcohol a day prior to the test.

Study Design

Observational Model: Defined Population, Time Perspective: Longitudinal


Locations

Country Name City State
Israel Hadassah Medical Organization Jerusalem

Sponsors (1)

Lead Sponsor Collaborator
Hadassah Medical Organization

Country where clinical trial is conducted

Israel, 

References & Publications (1)

Braden B, Faust D, Sarrazin U, Zeuzem S, Dietrich CF, Caspary WF, Sarrazin C. 13C-methacetin breath test as liver function test in patients with chronic hepatitis C virus infection. Aliment Pharmacol Ther. 2005 Jan 15;21(2):179-85. — View Citation

See also
  Status Clinical Trial Phase
Completed NCT01708889 - Pharmacokinetic Study of BMS-914143 in Participants With Normal Renal Function and Mild, Moderate, Severe and End-stage Renal Dysfunction Phase 1
Active, not recruiting NCT00563173 - Phase I/IIa Dose Ranging CHRONVAC-C® Study in Chronic HCV Patients Phase 1/Phase 2
Withdrawn NCT01813266 - Prospective Cohort Study: To Provide Evidence & Guidance in Hepatitis C Virus Screening, Comparing the New Birth Cohort Recommendations From the CDC, Versus Classical Traditional Strategies With Established Risk Factors
Completed NCT01121731 - A Phase I/II Clinical Trial With Interferon Alfa 5 in Treatment-Experienced Patients With Genotype-1 Chronic Hepatitis C Phase 1/Phase 2
Completed NCT00851890 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection Phase 2
Completed NCT04387539 - ٍٍSofosbuvir/Simeprevir/Daclatasvir/Ribavirin and HCV Genotype 4-infected Egyptian Experienced Participants Phase 1/Phase 2
Completed NCT04391985 - Sofosbuvir/Ombitasvir/Paritaprevir/ Ritonavir and Ribavirin for Hepatitis C Virus Genotype 4 Patients Phase 1/Phase 2
Completed NCT00770198 - sgp130 in Chronic Human Liver Disease N/A
Completed NCT04382937 - Ropeginterferon Alfa-2b (P1101) Phase 3 Study in Interferon Treatment-Naive Subjects With HCV Genotype 2 Infection Phase 3
Completed NCT00606528 - FGL2/Fibroleukin and Hepatitis C Virus Infection: A Predictor of Response to Antiviral Therapy N/A
Withdrawn NCT00255359 - Safety, Tolerability and Efficacy of XTL 2125 in HCV-Infected Patients Who Are Interferon-Alpha Non-Responders or Relapsers Phase 1
Completed NCT00570336 - Study of CTS-1027 in Hepatitis C Patients Phase 2
Completed NCT02292719 - A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir With Sofosbuvir With or Without Ribavirin in Adults With Chronic Hepatitis C Virus Infection Phase 2
Terminated NCT01080222 - A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection Phase 2
Completed NCT04385407 - Sofosbuvir With Ribavirin or Simeprevir With HCV GT4 Egyptian Patients Phase 2
Completed NCT04387526 - Sofosbuvir Plus Daclatasvir With or Without Ribavirin and Chronic HCV Genotype (GT) 4 Phase 2/Phase 3
Completed NCT00215865 - PEG-Interferon a-2b + Ribavirin for Treatment of Patients With Chronic Hepatitis C Who Have Previously Failed to Achieve a Sustained Virologic Response Following Interferon Alfa or Interferon a-2b + Ribavirin Therapy Phase 3